# **UC** Irvine

# **UC Irvine Previously Published Works**

### **Title**

ASSOCIATION BETWEEN PRE-KIDNEY TRANSPLANT SERUM SODIUM AND POST-TRANSPLANT OUTCOMES

#### **Permalink**

https://escholarship.org/uc/item/1sq3s8x0

## **Journal**

AMERICAN JOURNAL OF KIDNEY DISEASES, 79(4)

#### **ISSN**

0272-6386

#### **Authors**

Tantisattamo, Ekamol Streja, Elani Park, Christina et al.

## **Publication Date**

2022

# **Copyright Information**

This work is made available under the terms of a Creative Commons Attribution License, available at <a href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</a>

Peer reviewed



## 365

# ASSOCIATION BETWEEN PRE-KIDNEY TRANSPLANT SERUM SODIUM AND POST-TRANSPLANT OUTCOMES:

Ekamol Tantisattamo<sup>1</sup>, Elani Streja<sup>1</sup>, Christina Park<sup>1</sup>, Cachet Wenziger<sup>1</sup>, Jui-Ting Hsiung<sup>1</sup>, Dorry Segev<sup>2</sup>, Kamyar Kalantar-Zadeh<sup>1</sup>. <sup>1</sup>University of California Irvine; <sup>2</sup>Johns Hopkins University

Post-kidney transplant (KT) dysnatremia is associated with poor outcomes; however, post-KT outcomes related to pre-KT serum sodium(SNa) are unknown. This study aims to examine the association between SNa during 6-mo pre-KT and post-KT outcomes.

KT patients from the TCCKD study, a retrospective cohort study examining 102,477 US veterans with late-stage nondialysis-dependent CKD transitioning to kidney replacement therapy, were categorized based on 6-mo pre-KT SNa into 5 groups: <135, 135 - <137, 137 - <140(ref.), 140 - <143, and ≥143 mmol/L. The association between the pre-KT SNa and post-KT outcomes was examined by Cox regression.

Of 1,220 patients, the mean±SD age of 60±10 yrs, 1,172 patients were male, and baseline pre-KT SNa was 139±3 mmol/L. 107 patients died with a median time at risk of 2.35 yrs and the incidence rate was 3.37 death/100 person-yrs. There was a positive association between corrected SNa and all-cause mortality. However, the association was a J-shape with the lowest all-cause mortality rate in the reference group. Patients with the highest corrected SNa had a 2.15 times higher risk of all-cause mortality compared to the reference group(adjusted HR 2.15, 95%CI 0.95,4.87); while, the death risk was greatest among the highest uncorrected SNa group(HR 2.57, 95%CI 1.11,5.93). Using a spline term, the all-cause mortality increase was 7.48% for every 1 mmol/L increase in SNa among patients with the pre-KT corrected SNa  $\geq 138$  mmol/L(HR 1.07, 95%CI 0.97,1.19); whereas, the risk increased only 0.02% for patients with pre-KT corrected SNa <138 mmol/L(HR 1.0002, 95%CI 0.86,1.16)(Figure1). There were no differences in the CV and infectious mortality and death-censored and all-cause graft loss among different SNa groups. Length of stay(LOS) decreased 0.47 and 0.38 days for every 1 mmol/L increase in corrected and uncorrected SNa(p < 0.001 and 0.004, respectively).

High pre-KT SNa is associated with post-KT all-cause mortality, but with shortened LOS for KT admission.